These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9516230)

  • 21. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development.
    Pollock PM; Welch J; Hayward NK
    Cancer Res; 2001 Feb; 61(3):1154-61. PubMed ID: 11221846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel and recurrent p14 mutations in Italian familial melanoma.
    Binni F; Antigoni I; De Simone P; Majore S; Silipo V; Crisi A; Amantea A; Pacchiarini D; Castori M; De Bernardo C; Catricalà C; Grammatico P
    Clin Genet; 2010 Jun; 77(6):581-6. PubMed ID: 20132244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CDKN2A/CDK4 molecular study on 155 Italian subjects with familial and/or primary multiple melanoma.
    Majore S; De Simone P; Crisi A; Eibenschutz L; Binni F; Antigoni I; De Bernardo C; Catricalà C; Grammatico P
    Pigment Cell Melanoma Res; 2008 Apr; 21(2):209-11. PubMed ID: 18363633
    [No Abstract]   [Full Text] [Related]  

  • 24. Confirmed cancer trends in families of patients with multiple cancers including cutaneous melanoma.
    Nielsen K; Masback A; Bladstrom A; Lundgren L; Jonsson N; Borg A; Ingvar C; Olsson H
    Br J Dermatol; 2008 Feb; 158(2):429-31. PubMed ID: 18047508
    [No Abstract]   [Full Text] [Related]  

  • 25. Germline CDKN2A/p16 mutations are rare in multiple primary and familial malignant melanoma in German patients.
    Lukowsky A; Schäfer-Hesterberg G; Sterry W; Voit C
    J Dermatol Sci; 2008 Feb; 49(2):163-5. PubMed ID: 17890059
    [No Abstract]   [Full Text] [Related]  

  • 26. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors.
    Piepkorn M
    J Am Acad Dermatol; 2000 May; 42(5 Pt 1):705-22; quiz 723-6. PubMed ID: 10775844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations.
    Lal G; Liu L; Hogg D; Lassam NJ; Redston MS; Gallinger S
    Genes Chromosomes Cancer; 2000 Apr; 27(4):358-61. PubMed ID: 10719365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The INK4a-ARF locus: role in the genetic predisposition to familial melanoma and in skin carcinogenesis].
    Soufir N; Basset-Seguin N
    Bull Cancer; 2001 Nov; 88(11):1061-7. PubMed ID: 11741799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A marker for melanoma?
    Chande M
    Lancet; 2001 Aug; 358(9281):565. PubMed ID: 11520537
    [No Abstract]   [Full Text] [Related]  

  • 30. Multiple primary melanomas in a CDKN2A mutation carrier exposed to ionizing radiation.
    Eliason MJ; Hansen CB; Hart M; Porter-Gill P; Chen W; Sturm RA; Bowen G; Florell SR; Harris RM; Cannon-Albright LA; Swinyer L; Leachman SA
    Arch Dermatol; 2007 Nov; 143(11):1409-12. PubMed ID: 18025365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The atypical-mole syndrome and predisposition to melanoma.
    Wachsmuth RC; Harland M; Bishop JA
    N Engl J Med; 1998 Jul; 339(5):348-9. PubMed ID: 9696648
    [No Abstract]   [Full Text] [Related]  

  • 32. Loss of CDKN2A and p14ARF expression occurs frequently in human nonmelanoma skin cancers.
    Pacifico A; Goldberg LH; Peris K; Chimenti S; Leone G; Ananthaswamy HN
    Br J Dermatol; 2008 Feb; 158(2):291-7. PubMed ID: 18070208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDKN2A/p16 is inactivated in most melanoma cell lines.
    Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
    Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of multiple skin malignancies with multiple endocrine neoplasia type 1: coincidental or pathogenetically related?
    Baldauf C; Vortmeyer AO; Koch CA; Sticherling M
    Dermatology; 2009; 219(4):365-7. PubMed ID: 19141988
    [No Abstract]   [Full Text] [Related]  

  • 35. Melanoma and nonmelanoma skin cancer in patients with multiple tumours--evidence for new syndromes in a population-based study.
    Nielsen K; Ingvar C; Måsbäck A; Westerdahl J; Borg A; Sandberg T; Jonsson N; Nagel J; Olsson H
    Br J Dermatol; 2004 Mar; 150(3):531-6. PubMed ID: 15030338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High prevalence of germline CDKN2A mutations in Slovenian cutaneous malignant melanoma families.
    Hocevar M; Avbelj M; Perić B; Zgajnar J; Besić N; Battelino T
    Croat Med J; 2006 Dec; 47(6):851-4. PubMed ID: 17167857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Five novel somatic CDKN2/p16 mutations identified in melanoma, glioma and carcinoma of the pancreas. Mutations in brief no. 170. Online.
    Gretarsdóttir S; Olafsdóttir GH; Borg A
    Hum Mutat; 1998; 12(3):212. PubMed ID: 10651484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome.
    Rulyak SJ; Brentnall TA; Lynch HT; Austin MA
    Cancer; 2003 Aug; 98(4):798-804. PubMed ID: 12910525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.
    Knappskog S; Geisler J; Arnesen T; Lillehaug JR; Lønning PE
    Genes Chromosomes Cancer; 2006 Dec; 45(12):1155-63. PubMed ID: 17001621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Case 7-2004: hereditary melanoma and pancreatic cancer.
    Koopmann J; Goggins M; Hruban RH
    N Engl J Med; 2004 Jun; 350(25):2623-4; author reply 2623-4. PubMed ID: 15201425
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.